Core Viewpoint - Decent Holding Inc. has successfully closed an $8 million registered offering to support its business expansion and technological development in wastewater treatment services in China [1][2]. Group 1: Offering Details - The registered offering consisted of 13,333,333 Class A ordinary shares priced at $0.60 per share, along with warrants to purchase 26,666,666 additional Class A ordinary shares at an exercise price of $0.66 [1][2]. - Total gross proceeds from the offering amounted to $8 million before expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for business expansion, product research and development, promoting river water quality management services, upgrading wastewater treatment technologies, and recruiting talent [2]. Group 3: Legal and Regulatory Framework - The offering was conducted under an effective registration statement filed with the U.S. Securities and Exchange Commission (SEC) and became effective on November 6, 2025 [4]. - D. Boral Capital LLC served as the sole placement agent for the offering, with Ortoli Rosenstadt LLP and Crone Law Group, P.C. providing legal counsel [3]. Group 4: Company Overview - Decent Holding Inc. specializes in wastewater treatment, ecological river restoration, and microbial products for pollutant removal and water quality enhancement through its subsidiary, Shandong Dingxin Ecology Environmental Co., Ltd. [6].

Core Viewpoint - Decent Holding Inc. has announced a registered offering of US$8 million, consisting of 13,333,333 Class A ordinary shares priced at US$0.60 per share, along with warrants for additional shares, aimed at funding various business initiatives [1][2]. Group 1: Offering Details - The registered offering includes 13,333,333 Class A ordinary shares at a public offering price of US$0.60 per share, and warrants to purchase 26,666,666 Class A ordinary shares [1]. - The gross proceeds from the offering are expected to be approximately US$8 million before deducting commissions and offering expenses [1]. - The offering is expected to close on or about November 12, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for business expansion and launching additional offices [2]. - Funds will also be allocated for product research and development, promoting river water quality management services, and expanding river water treatment services [2]. - The company plans to invest in the development and upgrade of wastewater treatment technologies and recruit talents in research, development, and management [2]. Group 3: Legal and Regulatory Information - The offering is being conducted under an effective registration statement on Form F-1, which became effective on November 6, 2025 [4]. - The offering is made only by means of a prospectus that is part of the effective registration statement [4]. - D. Boral Capital LLC is acting as the sole placement agent for the offering, with Ortoli Rosenstadt LLP and Crone Law Group, P.C. serving as U.S. counsel [3].

Company Overview - WORK Medical Technology Group LTD is a supplier of medical devices in China, operating through its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and other subsidiaries [8] - The company develops and manufactures Class I and II medical devices, including customized and multifunctional masks, and sells disposable medical devices [8] - WORK Medical Technology has a diverse product portfolio comprising 21 products, with sales in 34 provincial-level administrative regions in China and exports to over 30 countries [8] - The company has received multiple quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration, allowing entry into the U.S. market [8] Offering Details - The company closed a registered offering, selling an aggregate of 10,000,000 ordinary units at an offering price of $0.50 per unit, resulting in gross proceeds of approximately $5 million [2][4] - Each ordinary unit consists of one Class A ordinary share, one Series A warrant, and one Series B warrant, both with an exercise price of $1.00 [3] - The Series A warrants expire in 12 months, while the Series B warrants expire in 3 months, and both are immediately exercisable upon issuance [3] Underwriting and Regulatory Compliance - Univest Securities, LLC acted as the sole book-running manager for the offering [4] - The offering was made pursuant to a registration statement on Form F-1, which was declared effective by the U.S. Securities and Exchange Commission [5]

Core Viewpoint - WORK Medical Technology Group LTD has successfully closed a registered offering of 10,000,000 ordinary units at a price of $0.50 per unit, raising a total of $5.0 million before expenses [1][3]. Summary by Sections Offering Details - Each ordinary unit consists of one Class A ordinary share, one Series A warrant, and one Series B warrant, both with an exercise price of $1.00 [2]. - The Series A warrants expire in 12 months, while the Series B warrants expire in 3 months [2]. - The offering was conducted on a firm commitment basis, with Univest Securities, LLC serving as the sole book-running manager [4]. Use of Proceeds - Proceeds from the offering will be allocated for upgrading production equipment, investing in research and development, hiring experienced employees for compliance improvements, and general corporate purposes [3]. Company Overview - WORK Medical Technology Group LTD is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices [6]. - The company has a diverse product portfolio of 21 products, including customized masks and medical consumables, sold in 34 regions in China and over 30 countries globally [6]. - The company has received multiple quality-related manufacturing designations and has registered 17 products with the U.S. FDA for market entry in the U.S. [6].

Core Viewpoint - WORK Medical Technology Group LTD is conducting a registered offering of 10,000,000 ordinary and pre-funded units to raise funds for various corporate purposes, including upgrading production equipment and R&D investments [1][3]. Group 1: Offering Details - The offering price is set at $0.50 per Ordinary Unit and $0.4995 per Pre-funded Unit [1]. - Each Ordinary Unit includes one Class A ordinary share, one Series A warrant, and one Series B warrant, while each Pre-funded Unit consists of one pre-funded warrant, one Series A warrant, and one Series B warrant [2]. - The Company expects to receive gross proceeds of $5.0 million from the offering before deducting expenses [3]. Group 2: Use of Proceeds - Proceeds will be allocated for upgrading production equipment, investing in R&D, hiring experienced employees for compliance improvements, and general corporate purposes [3]. Group 3: Company Overview - WORK Medical is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices, with a diverse product portfolio of 21 products [6]. - The Company has sold products in 34 provincial-level regions in China and in over 30 countries globally, with 17 products registered with the U.S. FDA [6].